These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 15388461)

  • 41. Update on Clostridium difficile-induced colitis, Part 2.
    Reinke CM; Messick CR
    Am J Hosp Pharm; 1994 Aug; 51(15):1892-901; quiz 1958-9. PubMed ID: 7942924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metronidazole resistance in Clostridium difficile.
    Johnson S; Sanchez JL; Gerding DN
    Clin Infect Dis; 2000 Aug; 31(2):625-6. PubMed ID: 10987742
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
    Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
    Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Role of Clostridium difficile infection in the relapse of ulcerative colitis].
    Vilalta Castel E; Alcázar Montero MS; Navarro Gaspar C; Gimeno Aranguez M
    An Med Interna; 2002 Dec; 19(12):637-9. PubMed ID: 12593034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection.
    Bartlett JG
    Clin Infect Dis; 2008 May; 46(10):1489-92. PubMed ID: 18419480
    [No Abstract]   [Full Text] [Related]  

  • 49. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Tart SB
    J Pharm Pract; 2013 Oct; 26(5):488-90. PubMed ID: 23940121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical manifestations, treatment and control of infections caused by Clostridium difficile.
    Bouza E; Muñoz P; Alonso R
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():57-64. PubMed ID: 15997485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces].
    Nieuwdorp M; van Nood E; Speelman P; van Heukelem HA; Jansen JM; Visser CE; Kuijper EJ; Bartelsman JF; Keller JJ
    Ned Tijdschr Geneeskd; 2008 Aug; 152(35):1927-32. PubMed ID: 18808083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective effect of a mixture of kefir-isolated lactic acid bacteria and yeasts in a hamster model of Clostridium difficile infection.
    Bolla PA; Carasi P; Bolla Mde L; De Antoni GL; Serradell Mde L
    Anaerobe; 2013 Jun; 21():28-33. PubMed ID: 23542116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clindamycin-induced colitis.
    Fekety R; Silva J; Browne RA; Rifkin GD; Ebright JR
    Am J Clin Nutr; 1979 Jan; 32(1):244-50. PubMed ID: 760500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
    Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
    Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of bismuth subsalicylate on Clostridium difficile colitis in hamsters.
    Chang TW; Dong MY; Gorbach SL
    Rev Infect Dis; 1990; 12 Suppl 1():S57-8. PubMed ID: 2305177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.
    Swanson RN; Hardy DJ; Shipkowitz NL; Hanson CW; Ramer NC; Fernandes PB; Clement JJ
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1108-11. PubMed ID: 1929250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clostridium difficile--a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis.
    Borriello SP; Ketley JM; Mitchell TJ; Barclay FE; Welch AR; Price AB; Stephen J
    J Med Microbiol; 1987 Aug; 24(1):53-64. PubMed ID: 3612744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.
    Louie TJ; Peppe J; Watt CK; Johnson D; Mohammed R; Dow G; Weiss K; Simon S; John JF; Garber G; Chasan-Taber S; Davidson DM;
    Clin Infect Dis; 2006 Aug; 43(4):411-20. PubMed ID: 16838228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
    Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
    J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.
    Johnson S; Schriever C; Galang M; Kelly CP; Gerding DN
    Clin Infect Dis; 2007 Mar; 44(6):846-8. PubMed ID: 17304459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.